Global Blood Therapeutics (NASDAQ:GBT)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a research report issued on Friday. They currently have a $73.00 price objective on the stock. Wedbush’s price objective would suggest a potential upside of 101.38% from the stock’s previous close.

GBT has been the subject of several other research reports. BidaskClub raised Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Needham & Company LLC assumed coverage on Global Blood Therapeutics in a research note on Wednesday, September 20th. They issued a “buy” rating and a $51.00 price target for the company. Morgan Stanley reissued an “overweight” rating and issued a $56.00 price target (up previously from $51.00) on shares of Global Blood Therapeutics in a research note on Friday, October 6th. Zacks Investment Research raised Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research note on Tuesday, October 10th. Finally, Oppenheimer set a $53.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $62.07.

Shares of Global Blood Therapeutics (NASDAQ:GBT) traded down $3.15 on Friday, reaching $36.25. The company’s stock had a trading volume of 3,989,802 shares, compared to its average volume of 1,041,337. Global Blood Therapeutics has a fifty-two week low of $13.35 and a fifty-two week high of $45.85.

Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same period last year, the business earned ($0.58) earnings per share. equities analysts forecast that Global Blood Therapeutics will post -2.55 earnings per share for the current year.

In other Global Blood Therapeutics news, Director Charles J. Homcy sold 70,000 shares of the stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $33.97, for a total value of $2,377,900.00. Following the transaction, the director now owns 83,328 shares in the company, valued at $2,830,652.16. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jung Choi sold 3,000 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the transaction, the insider now owns 140,055 shares in the company, valued at approximately $4,201,650. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 88,500 shares of company stock worth $3,003,350. 5.30% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in GBT. State Street Corp boosted its holdings in Global Blood Therapeutics by 217.9% in the second quarter. State Street Corp now owns 2,138,323 shares of the company’s stock worth $58,479,000 after acquiring an additional 1,465,595 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Global Blood Therapeutics by 189.5% in the third quarter. Point72 Asset Management L.P. now owns 2,022,700 shares of the company’s stock worth $62,805,000 after acquiring an additional 1,323,934 shares in the last quarter. Janus Henderson Group PLC bought a new position in Global Blood Therapeutics in the second quarter worth approximately $26,919,000. BlackRock Inc. boosted its holdings in Global Blood Therapeutics by 30.0% in the second quarter. BlackRock Inc. now owns 3,404,538 shares of the company’s stock worth $93,114,000 after acquiring an additional 785,691 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Global Blood Therapeutics by 15.7% in the second quarter. Vanguard Group Inc. now owns 2,933,251 shares of the company’s stock worth $80,224,000 after acquiring an additional 397,271 shares in the last quarter. Institutional investors and hedge funds own 90.48% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Global Blood Therapeutics (GBT) Stock Rating Reaffirmed by Wedbush” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/15/global-blood-therapeutics-gbt-stock-rating-reaffirmed-by-wedbush.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.